Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × Celecoxib × Clear all

Phase

Phase 1 3 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Head and Neck Neoplasms 3 Colorectal Neoplasms 3 Uterine Cervical Neoplasms 2 Melanoma 2 Triple Negative Breast Neoplasms 1 Tobacco Use Disorder 1 Squamous Cell Carcinoma of Head and Neck 1 Smoking 1 Sarcoma 1 Recurrence 1 Precancerous Conditions 1 Pharyngeal Neoplasms 1 Peritoneal Neoplasms 1 Paranasal Sinus Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Neoplasm, Residual 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Lung Neoplasms 1 Liver Neoplasms 1 Laryngeal Neoplasms 1 Glioblastoma 1 Colonic Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Hepatocellular 1 Breast Neoplasms 1 Biomarker Change Linked to Breast Cancer 1

Interventions

pembrolizumab 37 Nivolumab 24 Gemcitabine 24 Paclitaxel 16 Carboplatin 14 Cyclophosphamide 12 Cisplatin 12 Ipilimumab 10 Capecitabine 10 Irinotecan 8 Docetaxel 8 Dexamethasone 8 Bevacizumab 8 130-nm albumin-bound paclitaxel 8 Rituximab 7 Albumin-Bound Paclitaxel 7 Temozolomide 6 Sorafenib 6 Pemetrexed 6 Cetuximab 6 Azacitidine 6 Ascorbic Acid 6 spartalizumab 5 lenvatinib 5 fludarabine 5 cemiplimab 5 Radiotherapy 5 ibrutinib 4 avelumab 4 atezolizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00581971 2013-04-25

RAD0201

University of Alabama at Birmingham

Phase 1/2 Completed

30 enrolled 8 charts

Head and Neck Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡